Institute seminar November 11th 12:00 Anne Hansen Ree and Kjersti Flatmark

Publications by Anne Hansen Ree

144 publications found

Publications 2024

1. Cabrero-de Las Heras S, Hernández-Yagüe X, González A, Losa F, Soler G, Bugés C, Baraibar I, Esteve A, Pardo-Cea MÁ, Ree AH, Martínez-Bosch N, Nieva M, Musulén E, Meltzer S, Lobato T, Vendrell-Ayats C, Queralt C, Navarro P, Montagut C, Grau-Leal F, Camacho D, Legido R, Mulet-Margalef N, Martínez-Balibrea E (2024)
   Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment
   Biomed Pharmacother, 176, 116857
   DOI 10.1016/j.biopha.2024.116857, PubMed 38850664
2. Knuth F, Tohidinezhad F, Winter RM, Bakke KM, Negård A, Holmedal SH, Ree AH, Meltzer S, Traverso A, Redalen KR (2024)
   Quantitative MRI-based radiomics analysis identifies blood flow feature associated to overall survival for rectal cancer patients
   Sci Rep, 14 (1), 258
   DOI 10.1038/s41598-023-50966-9, PubMed 38167665
3. Mecinaj A, Gulati G, Ree AH, Gravdehaug B, Røsjø H, Steine K, Wisløff T, Geisler J, Omland T, Heck SL (2024)
   Impact of the ESC Cardio-Oncology Guidelines Biomarker Criteria on Incidence of Cancer Therapy-Related Cardiac Dysfunction
   JACC CardioOncol, 6 (1), 83-95
   DOI 10.1016/j.jaccao.2023.10.008, PubMed 38510299
4. O'Brien RM, Meltzer S, Buckley CE, Heeran AB, Nugent TS, Donlon NE, Reynolds JV, Ree AH, Redalen KR, Hafeez A, O'Ríordáin DS, Hannon RA, Neary P, Kalbassi R, Mehigan BJ, McCormick PH, Dunne C, Kelly ME, Larkin JO, O'Sullivan J, Lysaght J, Lynam-Lennon N (2024)
   Complement is increased in treatment resistant rectal cancer and modulates radioresistance
   Cancer Lett, 604, 217253
   DOI 10.1016/j.canlet.2024.217253, PubMed 39278399
5. Ree AH, Høye E, Esbensen Y, Beitnes AR, Negård A, Bernklev L, Tetlie LK, Fretland ÅA, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Nilsen HL, Flatmark K, Meltzer S (2024)
   Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade
   Oncoimmunology, 13 (1), 2372886
   DOI 10.1080/2162402X.2024.2372886, PubMed 38952672
6. Ree AH, Šaltytė Benth J, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Johansen C, Negård A, Bjørnetrø T, Nilsen HL, Berg JP, Flatmark K, Meltzer S (2024)
   First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial
   Br J Cancer, 130 (12), 1921-1928
   DOI 10.1038/s41416-024-02696-6, PubMed 38664577

Publications 2023

1. Bakke KM, Meltzer S, Grøvik E, Negård A, Holmedal SH, Mikalsen LTG, Færden AE, Lyckander LG, Julbø FMI, Bjørnerud A, Gjesdal KI, Ree AH, Redalen KR (2023)
   Imaging the tumour microenvironment in rectal cancer: Decline in tumour blood flow during radiotherapy predicts good outcome
   Phys Imaging Radiat Oncol, 25, 100417
   DOI 10.1016/j.phro.2023.100417, PubMed 36718357
2. Bjørnetrø T, Bousquet PA, Redalen KR, Trøseid AS, Lüders T, Stang E, Sanabria AM, Johansen C, Fuglestad AJ, Kersten C, Meltzer S, Ree AH (2023)
   Next-generation sequencing reveals mitogenome diversity in plasma extracellular vesicles from colorectal cancer patients
   BMC Cancer, 23 (1), 650
   DOI 10.1186/s12885-023-11092-x, PubMed 37438741
3. Buckley CE, Yin X, Meltzer S, Ree AH, Redalen KR, Brennan L, O'Sullivan J, Lynam-Lennon N (2023)
   Energy Metabolism Is Altered in Radioresistant Rectal Cancer
   Int J Mol Sci, 24 (8)
   DOI 10.3390/ijms24087082, PubMed 37108244
4. Larsen TL, Svalastoga M, Brekke J, Enden T, Frøen H, Garresori H, Jacobsen EM, Paulsen PQ, Porojnicu AC, Ree AH, Torfoss D, Velle EO, Wik HS, Ghanima W, Sandset PM, Dahm AEA (2023)
   Arterial events in cancer patients treated with apixaban for venous thrombosis
   Thromb Res, 228, 128-133
   DOI 10.1016/j.thromres.2023.05.017, PubMed 37327527
5. Nygaard V, Ree AH, Dagenborg VJ, Børresen-Dale AL, Edwin B, Fretland ÅA, Grzyb K, Haugen MH, Mælandsmo GM, Flatmark K (2023)
   A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases
   Cancer Res Commun, 3 (2), 235-244
   DOI 10.1158/2767-9764.CRC-22-0295, PubMed 36968142

Publications 2022

1. Ambrosini M, Del Re M, Manca P, Hendifar A, Drilon A, Harada G, Ree AH, Klempner S, Mælandsmo GM, Flatmark K, Russnes HG, Cleary JM, Singh H, Sottotetti E, Martinetti A, Randon G, Sartore-Bianchi A, Capone I, Milione M, Di Bartolomeo M, Pietrantonio F (2022)
   ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series
   JCO Precis Oncol, 6 (1), e2200015
   DOI 10.1200/PO.22.00015, PubMed 35476549
2. Fuglestad AJ, Meltzer S, Ree AH, McMillan DC, Park JH, Kersten C (2022)
   The clinical value of C-reactive protein and its association with tumour location in patients undergoing curative surgery for colorectal cancer - a ScotScan collaborative study
   Acta Oncol, 61 (10), 1248-1255
   DOI 10.1080/0284186X.2022.2117572, PubMed 36068730
3. Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
   Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
   J Transl Med, 20 (1), 225
   DOI 10.1186/s12967-022-03432-5, PubMed 35568909
4. Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
   Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
   J Transl Med, 20 (1), 317
   DOI 10.1186/s12967-022-03518-0, PubMed 35841045
5. Høye E, Dagenborg VJ, Torgunrud A, Lund-Andersen C, Fretland ÅA, Lorenz S, Edwin B, Hovig E, Fromm B, Inderberg EM, Greiff V, Ree AH, Flatmark K (2022)
   T cell receptor repertoire sequencing reveals chemotherapy-driven clonal expansion in colorectal liver metastases
   Gigascience, 12
   DOI 10.1093/gigascience/giad032, PubMed 37161965
6. Larsen TL, Garresori H, Brekke J, Enden T, Frøen H, Jacobsen EM, Quist-Paulsen P, Porojnicu AC, Ree AH, Torfoss D, Osvik Velle E, Skuterud Wik H, Ghanima W, Sandset PM, Dahm AEA (2022)
   Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up
   J Thromb Haemost, 20 (5), 1166-1181
   DOI 10.1111/jth.15666, PubMed 35114046
7. Larsen TL, Garresori H, Brekke J, Enden T, Frøen H, Jacobsen EM, Quist-Paulsen P, Porojnicu AC, Ree AH, Torfoss D, Velle EO, Wik HS, Ghanima W, Sandset PM, Dahm AEA (2022)
   "Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up": Reply
   J Thromb Haemost, 20 (8), 1937-1939
   DOI 10.1111/jth.15774, PubMed 35859282
8. Malenge MM, Maaland AF, Repetto-Llamazares A, Middleton B, Nijland M, Visser L, Patzke S, Heyerdahl H, Kolstad A, Stokke T, Ree AH, Dahle J (2022)
   Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro
   PLoS One, 17 (4), e0267543
   DOI 10.1371/journal.pone.0267543, PubMed 35486574
9. Meltzer S, Negård A, Bakke KM, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Flatmark K, Ree AH (2022)
   Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer
   Br J Cancer, 127 (12), 2227-2233
   DOI 10.1038/s41416-022-02004-0, PubMed 36229579
10. Ree AH, Mælandsmo GM, Flatmark K, Russnes HG, Gómez Castañeda M, Aas E (2022)
    Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer - the MetAction precision medicine study
    Acta Oncol, 61 (8), 955-962
    DOI 10.1080/0284186X.2022.2098053, PubMed 35943168

Publications 2021

1. Abrahamsson H, Meltzer S, Hagen VN, Johansen C, Bousquet PA, Redalen KR, Ree AH (2021)
   Sex disparities in vitamin D status and the impact on systemic inflammation and survival in rectal cancer
   BMC Cancer, 21 (1), 535
   DOI 10.1186/s12885-021-08260-2, PubMed 33975557
2. Bjørnetrø T, Steffensen LA, Vestad B, Brusletto BS, Olstad OK, Trøseid AM, Aass HCD, Haug KBF, Llorente A, Bøe SO, Lång A, Samiappan R, Redalen KR, Øvstebø R, Ree AH (2021)
   Uptake of circulating extracellular vesicles from rectal cancer patients and differential responses by human monocyte cultures
   FEBS Open Bio, 11 (3), 724-740
   DOI 10.1002/2211-5463.13098, PubMed 33512765
3. Bousquet PA, Meltzer S, Fuglestad AJ, Lüders T, Esbensen Y, Juul HV, Johansen C, Lyckander LG, Bjørnetrø T, Inderberg EM, Kersten C, Redalen KR, Ree AH (2021)
   The mitochondrial DNA constitution shaping T-cell immunity in patients with rectal cancer at high risk of metastatic progression
   Clin Transl Oncol, 24 (6), 1157-1167
   DOI 10.1007/s12094-021-02756-w, PubMed 34961902
4. Dagenborg VJ, Marshall SE, Grzyb K, Fretland ÅA, Lund-Iversen M, Mælandsmo GM, Ree AH, Edwin B, Yaqub S, Flatmark K (2021)
   Low Concordance Between T-Cell Densities in Matched Primary Tumors and Liver Metastases in Microsatellite Stable Colorectal Cancer
   Front Oncol, 11, 671629
   DOI 10.3389/fonc.2021.671629, PubMed 34178659
5. Heck SL, Mecinaj A, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, Røsjø H, Steine K, Geisler J, Gulati G, Omland T (2021)
   Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol
   Circulation, 143 (25), 2431-2440
   DOI 10.1161/CIRCULATIONAHA.121.054698, PubMed 33993702
6. Knuth F, Adde IA, Huynh BN, Groendahl AR, Winter RM, Negård A, Holmedal SH, Meltzer S, Ree AH, Flatmark K, Dueland S, Hole KH, Seierstad T, Redalen KR, Futsaether CM (2021)
   MRI-based automatic segmentation of rectal cancer using 2D U-Net on two independent cohorts
   Acta Oncol, 61 (2), 255-263
   DOI 10.1080/0284186X.2021.2013530, PubMed 34918621
7. Meltzer S, Torgunrud A, Abrahamsson H, Solbakken AM, Flatmark K, Dueland S, Bakke KM, Bousquet PA, Negård A, Johansen C, Lyckander LG, Larsen FO, Schou JV, Redalen KR, Ree AH (2021)
   The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer
   Br J Cancer, 125 (2), 240-246
   DOI 10.1038/s41416-021-01377-y, PubMed 33837301
8. Ree AH (2021)
   Precision cancer medicine - still expedient for the few
   Tidsskr Nor Laegeforen, 141 (5)
   DOI 10.4045/tidsskr.20.0980, PubMed 33754663
9. Ree AH (2021)
   Precision cancer medicine still expedient for the few
   Tidsskr. Nor. Laegeforen., 141 (5), 424-426

Publications 2020

1. Abrahamsson H, Jensen BV, Berven LL, Nielsen DL, Šaltytė Benth J, Johansen JS, Larsen FO, Johansen JS, Ree AH (2020)
   Antitumour immunity invoked by hepatic arterial infusion of first-line oxaliplatin predicts durable colorectal cancer control after liver metastasis ablation: 8-12 years of follow-up
   Int J Cancer, 146 (7), 2019-2026
   DOI 10.1002/ijc.32847, PubMed 31872440
2. Bakke KM, Meltzer S, Grøvik E, Negård A, Holmedal SH, Gjesdal KI, Bjørnerud A, Ree AH, Redalen KR (2020)
   Sex Differences and Tumor Blood Flow from Dynamic Susceptibility Contrast MRI Are Associated with Treatment Response after Chemoradiation and Long-term Survival in Rectal Cancer
   Radiology, 297 (2), 352-360
   DOI 10.1148/radiol.2020200287, PubMed 32870132
3. Dagenborg VJ, Marshall SE, Yaqub S, Grzyb K, Boye K, Lund-Iversen M, Høye E, Berstad AE, Fretland ÅA, Edwin B, Ree AH, Flatmark K (2020)
   Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases
   Cancer Biol Ther, 21 (5), 432-440
   DOI 10.1080/15384047.2020.1721252, PubMed 32098573
4. Hannevik TL, Brekke J, Enden T, Frøen H, Garresori H, Jacobsen EM, Paulsen PQ, Porojnicu AC, Ree AH, Torfoss D, Velle EO, Wik HS, Ghanima W, Sandset PM, Dahm AEA (2020)
   Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism
   Thromb Res, 196, 238-244
   DOI 10.1016/j.thromres.2020.08.042, PubMed 32919178
5. Kalanxhi E, Meltzer S, Ree AH (2020)
   Immune-Modulating Effects of Conventional Therapies in Colorectal Cancer
   Cancers (Basel), 12 (8)
   DOI 10.3390/cancers12082193, PubMed 32781554
6. Malenge MM, Patzke S, Ree AH, Stokke T, Ceuppens P, Middleton B, Dahle J, Repetto-Llamazares AHV (2020)
   ¹⁷⁷Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma
   J Nucl Med, 61 (10), 1468-1475
   DOI 10.2967/jnumed.119.237230, PubMed 32245896
7. Meltzer S, Bjørnetrø T, Lyckander LG, Flatmark K, Dueland S, Samiappan R, Johansen C, Kalanxhi E, Ree AH, Redalen KR (2020)
   Corrigendum to "Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer" [Transl Oncol 12 (8) (2019) 1038-1044]
   Transl Oncol, 13 (1), 122-124
   DOI 10.1016/j.tranon.2019.09.005, PubMed 31843135
8. Ree AH, Nygaard V, Boye K, Heinrich D, Dueland S, Bergheim IR, Johansen C, Beiske K, Negård A, Lund-Iversen M, Nygaard V, Hovig E, Nakken S, Nasser S, Julsrud L, Reisse CH, Ruud EA, Kristensen VN, Flørenes VA, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Russnes HG, Mælandsmo GM, Flatmark K (2020)
   Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
   Acta Oncol, 59 (7), 733-740
   DOI 10.1080/0284186X.2020.1742377, PubMed 32208873

Publications 2019

1. Abrahamsson H, Porojnicu AC, Lindstrøm JC, Dueland S, Flatmark K, Hole KH, Seierstad T, Moan J, Redalen KR, Meltzer S, Ree AH (2019)
   High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer
   BMC Cancer, 19 (1), 488
   DOI 10.1186/s12885-019-5724-z, PubMed 31122213
2. Bains SJ, Abrahamsson H, Flatmark K, Dueland S, Hole KH, Seierstad T, Redalen KR, Meltzer S, Ree AH (2019)
   Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer
   Cancer Immunol Immunother, 69 (3), 355-364
   DOI 10.1007/s00262-019-02458-x, PubMed 31893287
3. Bakke KM, Grøvik E, Meltzer S, Negård A, Holmedal SH, Mikalsen LTG, Lyckander LG, Ree AH, Gjesdal KI, Redalen KR, Bjørnerud A (2019)
   Comparison of Intravoxel incoherent motion imaging and multiecho dynamic contrast-based MRI in rectal cancer
   J Magn Reson Imaging, 50 (4), 1114-1124
   DOI 10.1002/jmri.26740, PubMed 30945379
4. Bjørnetrø T, Redalen KR, Meltzer S, Thusyanthan NS, Samiappan R, Jegerschöld C, Handeland KR, Ree AH (2019)
   An experimental strategy unveiling exosomal microRNAs 486-5p, 181a-5p and 30d-5p from hypoxic tumour cells as circulating indicators of high-risk rectal cancer
   J Extracell Vesicles, 8 (1), 1567219
   DOI 10.1080/20013078.2019.1567219, PubMed 30728923
5. Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM (2019)
   A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
   Transl Oncol, 12 (7), 951-958
   DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111
6. Meltzer S, Bakke KM, Rød KL, Negård A, Flatmark K, Solbakken AM, Kristensen AT, Fuglestad AJ, Kersten C, Dueland S, Seierstad T, Hole KH, Lyckander LG, Larsen FO, Schou JV, Patrick Brown D, Abrahamsson H, Redalen KR, Ree AH (2019)
   Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors?
   Clin Transl Radiat Oncol, 21, 5-10
   DOI 10.1016/j.ctro.2019.11.006, PubMed 31872084
7. Meltzer S, Bjørnetrø T, Lyckander LG, Flatmark K, Dueland S, Samiappan R, Johansen C, Kalanxhi E, Ree AH, Redalen KR (2019)
   Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer
   Transl Oncol, 12 (8), 1038-1044
   DOI 10.1016/j.tranon.2019.04.014, PubMed 31146167
8. Ree AH, Nygaard V, Russnes HG, Heinrich D, Nygaard V, Johansen C, Bergheim IR, Hovig E, Beiske K, Negård A, Børresen-Dale AL, Flatmark K, Mælandsmo GM (2019)
   Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
   Cancer Immunol Res, 7 (5), 701-706
   DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006

Publications 2018

1. Bousquet PA, Meltzer S, Sønstevold L, Esbensen Y, Dueland S, Flatmark K, Sitter B, Bathen TF, Seierstad T, Redalen KR, Eide L, Ree AH (2018)
   Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer
   Transl Oncol, 12 (1), 76-83
   DOI 10.1016/j.tranon.2018.09.010, PubMed 30273860
2. Boysen AK, Sørensen BS, Lefevre AC, Abrantes R, Johansen JS, Jensen BV, Schou JV, Larsen FO, Nielsen D, Taflin H, Gustavson B, Wettergren Y, Sorensen BS, Ree AH, Dueland S, Pallisgaard N, Spindler KL (2018)
   Methodological development and biological observations of cell free DNA with a simple direct fluorescent assay in colorectal cancer
   Clin Chim Acta, 487, 107-111
   DOI 10.1016/j.cca.2018.09.029, PubMed 30240586
3. Gopinathan U, Redalen KR, Trøseid AM, Kierulf P, Brandtzaeg P, Ree AH, Berg JP, Øvstebø R (2018)
   Large-scale reduction of tyrosine kinase activities in human monocytes stimulated in vitro with N. meningitidis
   PLoS One, 13 (1), e0181912
   DOI 10.1371/journal.pone.0181912, PubMed 29357362
4. Heck SL, Gulati G, Hoffmann P, von Knobelsdorff-Brenkenhoff F, Storås TH, Ree AH, Gravdehaug B, Røsjø H, Steine K, Geisler J, Schulz-Menger J, Omland T (2018)
   Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: the PRADA trial
   Eur Heart J Cardiovasc Imaging, 19 (5), 544-552
   DOI 10.1093/ehjci/jex159, PubMed 29106497
5. Kalanxhi E, Meltzer S, Schou JV, Larsen FO, Dueland S, Flatmark K, Jensen BV, Hole KH, Seierstad T, Redalen KR, Nielsen DL, Ree AH (2018)
   Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer
   Br J Cancer, 118 (10), 1322-1328
   DOI 10.1038/s41416-018-0085-y, PubMed 29695770

Publications 2017

1. Bakke KM, Hole KH, Dueland S, Grøholt KK, Flatmark K, Ree AH, Seierstad T, Redalen KR (2017)
   Diffusion-weighted magnetic resonance imaging of rectal cancer: tumour volume and perfusion fraction predict chemoradiotherapy response and survival
   Acta Oncol, 56 (6), 813-818
   DOI 10.1080/0284186X.2017.1287951, PubMed 28464745
2. Gulati G, Heck SL, Røsjø H, Ree AH, Hoffmann P, Hagve TA, Norseth J, Gravdehaug B, Steine K, Geisler J, Omland T (2017)
   Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study
   J Am Heart Assoc, 6 (11)
   DOI 10.1161/JAHA.117.006513, PubMed 29118031
3. Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA et al. (2017)
   Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
   ESMO Open, 2 (2), e000158
   DOI 10.1136/esmoopen-2017-000158, PubMed 28761742
4. Østrup O, Dagenborg VJ, Rødland EA, Skarpeteig V, Silwal-Pandit L, Grzyb K, Berstad AE, Fretland ÅA, Mælandsmo GM, Børresen-Dale AL, Ree AH, Edwin B, Nygaard V, Flatmark K (2017)
   Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases
   Oncotarget, 8 (44), 76290-76304
   DOI 10.18632/oncotarget.19350, PubMed 29100312

Publications 2016

1. Dueland S, Ree AH, Grøholt KK, Saelen MG, Folkvord S, Hole KH, Seierstad T, Larsen SG, Giercksky KE, Wiig JN, Boye K, Flatmark K (2016)
   Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome
   Clin Oncol (R Coll Radiol), 28 (8), 532-9
   DOI 10.1016/j.clon.2016.01.014, PubMed 26888115
2. Flatmark K, Saelen MG, Hole KH, Abrahamsen TW, Fleten KG, Hektoen HH, Redalen KR, Seierstad T, Dueland S, Ree AH (2016)
   Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity?
   Radiother Oncol, 119 (3), 505-11
   DOI 10.1016/j.radonc.2016.02.020, PubMed 26968754
3. Grøvik E, Redalen KR, Storås TH, Negård A, Holmedal SH, Ree AH, Meltzer S, Bjørnerud A, Gjesdal KI (2016)
   Dynamic multi-echo DCE- and DSC-MRI in rectal cancer: Low primary tumor K^trans and ΔR2* peak are significantly associated with lymph node metastasis
   J Magn Reson Imaging, 46 (1), 194-206
   DOI 10.1002/jmri.25566, PubMed 28001320
4. Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland Å, Storås TH, Hagve TA, Røsjø H, Steine K, Geisler J, Omland T (2016)
   Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol
   Eur Heart J, 37 (21), 1671-80
   DOI 10.1093/eurheartj/ehw022, PubMed 26903532
5. Jonsson M, Ragnum HB, Julin CH, Yeramian A, Clancy T, Frikstad KM, Seierstad T, Stokke T, Matias-Guiu X, Ree AH, Flatmark K, Lyng H (2016)
   Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition
   Br J Cancer, 115 (8), 929-939
   DOI 10.1038/bjc.2016.278, PubMed 27599042
6. Kalanxhi E, Hektoen HH, Meltzer S, Dueland S, Flatmark K, Ree AH (2016)
   Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening
   BMC Cancer, 16, 536
   DOI 10.1186/s12885-016-2601-x, PubMed 27461255
7. Kalanxhi E, Risberg K, Barua IS, Dueland S, Waagene S, Andersen SN, Pettersen SJ, Lindvall JM, Redalen KR, Flatmark K, Ree AH (2016)
   Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy
   Cancer Res Treat, 49 (2), 374-386
   DOI 10.4143/crt.2016.080, PubMed 27488871
8. Meltzer S, Kalanxhi E, Hektoen HH, Dueland S, Flatmark K, Redalen KR, Ree AH (2016)
   Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer
   Oncotarget, 7 (23), 34907-17
   DOI 10.18632/oncotarget.8995, PubMed 27145458
9. Ree AH (2016)
   Immune-modulating cancer therapy - back to the future
   Tidsskr Nor Laegeforen, 136 (19), 1605
   DOI 10.4045/tidsskr.16.0630, PubMed 27790877
10. Risberg K, Redalen KR, Sønstevold L, Bjørnetrø T, Sølvernes J, Ree AH (2016)
    Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells
    BMC Cancer, 16, 531
    DOI 10.1186/s12885-016-2600-y, PubMed 27461218

Publications 2015

1. Hektoen HH, Flatmark K, Andersson Y, Dueland S, Redalen KR, Ree AH (2015)
   Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer
   BMC Cancer, 15, 543
   DOI 10.1186/s12885-015-1557-6, PubMed 26205955
2. Hektoen HH, Ree AH, Redalen KR, Flatmark K (2015)
   Sulfamate inhibitor S4 influences carbonic anhydrase IX ectodomain shedding in colorectal carcinoma cells
   J Enzyme Inhib Med Chem, 31 (5), 779-86
   DOI 10.3109/14756366.2015.1069286, PubMed 26244271
3. Redalen KR, Sitter B, Bathen TF, Grøholt KK, Hole KH, Dueland S, Flatmark K, Ree AH, Seierstad T (2015)
   High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer
   Radiother Oncol, 118 (2), 393-8
   DOI 10.1016/j.radonc.2015.11.031, PubMed 26705680
4. Ree AH, Flatmark K, Saelen MG, Folkvord S, Dueland S, Geisler J, Redalen KR (2015)
   Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: opportunities for signaling-adapted therapies
   Crit Rev Oncol Hematol, 95 (1), 114-24
   DOI 10.1016/j.critrevonc.2015.01.003, PubMed 25624177
5. Ree AH, Redalen KR (2015)
   Personalized radiotherapy: concepts, biomarkers and trial design
   Br J Radiol, 88 (1051), 20150009
   DOI 10.1259/bjr.20150009, PubMed 25989697
6. Seierstad T, Hole KH, Grøholt KK, Dueland S, Ree AH, Flatmark K, Redalen KR (2015)
   MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer
   Br J Radiol, 88 (1051), 20150097
   DOI 10.1259/bjr.20150097, PubMed 25899892

Publications 2014

1. Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, Ward C, Meehan J, Kunkler IH, Langdon SP, Ree AH, Flatmark K, Lyng H, Calzada MJ, Peso LD, Landazuri MO, Görlach A, Flamm H, Kieninger J, Urban G, Weltin A, Singleton DC, Haider S, Buffa FM, Harris AL et al. (2014)
   Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium
   J Enzyme Inhib Med Chem, 30 (5), 689-721
   DOI 10.3109/14756366.2014.966704, PubMed 25347767
2. Ree AH, Meltzer S, Flatmark K, Dueland S, Kalanxhi E (2014)
   Biomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networks
   Int J Mol Sci, 15 (12), 22835-56
   DOI 10.3390/ijms151222835, PubMed 25501337
3. Ree AH, Saelen MG, Kalanxhi E, Østensen IH, Schee K, Røe K, Abrahamsen TW, Dueland S, Flatmark K (2014)
   Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy
   PLoS One, 9 (2), e89750
   DOI 10.1371/journal.pone.0089750, PubMed 24587009

Publications 2013

1. Gulati G, Heck SL, Ree AH, Gravdehaug B, Røsjø H, Steine K, Bratland Å, Hoffmann P, Geisler J, Omland T (2013)
   [Cardioprotective treatment during adjuvant cancer therapy]
   Tidsskr Nor Laegeforen, 133 (17), 1832-6
   DOI 10.4045/tidsskr.12.1514, PubMed 24042297
2. Hole KH, Larsen SG, Grøholt KK, Giercksky KE, Ree AH (2013)
   Magnetic resonance-guided histopathology for improved accuracy of tumor response evaluation of neoadjuvant treatment in organ-infiltrating rectal cancer
   Radiother Oncol, 107 (2), 178-83
   DOI 10.1016/j.radonc.2013.03.017, PubMed 23602370
3. Ragnum HB, Røe K, Holm R, Vlatkovic L, Nesland JM, Aarnes EK, Ree AH, Flatmark K, Seierstad T, Lilleby W, Lyng H (2013)
   Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer
   Int J Radiat Oncol Biol Phys, 87 (4), 753-60
   DOI 10.1016/j.ijrobp.2013.07.023, PubMed 24035332
4. Ree AH, Hollywood D (2013)
   Design and conduct of early-phase radiotherapy trials with targeted therapeutics: lessons from the PRAVO experience
   Radiother Oncol, 108 (1), 3-16
   DOI 10.1016/j.radonc.2013.06.007, PubMed 23830196
5. Røe K, Bratland Å, Vlatkovic L, Ragnum HB, Saelen MG, Olsen DR, Marignol L, Ree AH (2013)
   Hypoxic tumor kinase signaling mediated by STAT5A in development of castration-resistant prostate cancer
   PLoS One, 8 (5), e63723
   DOI 10.1371/journal.pone.0063723, PubMed 23675504
6. Tahiri A, Røe K, Ree AH, de Wijn R, Risberg K, Busch C, Lønning PE, Kristensen V, Geisler J (2013)
   Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma
   PLoS One, 8 (8), e72692
   DOI 10.1371/journal.pone.0072692, PubMed 24023633

Publications 2012

1. Heck SL, Gulati G, Ree AH, Schulz-Menger J, Gravdehaug B, Røsjø H, Steine K, Bratland A, Hoffmann P, Geisler J, Omland T (2012)
   Rationale and design of the prevention of cardiac dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial
   Cardiology, 123 (4), 240-7
   DOI 10.1159/000343622, PubMed 23207160
2. Ree AH (2012)
   Individualised treatment of metastatic cancer
   Tidsskr Nor Laegeforen, 132 (21), 2358-9
   DOI 10.4045/tidsskr.12.1130, PubMed 23160572
3. Ree AH, Kristensen AT, Saelen MG, de Wijn R, Edvardsen H, Jovanovic J, Abrahamsen TW, Dueland S, Flatmark K (2012)
   Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer
   PLoS One, 7 (11), e50806
   DOI 10.1371/journal.pone.0050806, PubMed 23226389
4. Røe K, Mikalsen LT, van der Kogel AJ, Bussink J, Lyng H, Ree AH, Marignol L, Olsen DR (2012)
   Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
   Radiat Oncol, 7, 75
   DOI 10.1186/1748-717X-7-75, PubMed 22621752
5. Saelen MG, Ree AH, Kristian A, Fleten KG, Furre T, Hektoen HH, Flatmark K (2012)
   Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma
   Radiat Oncol, 7, 165
   DOI 10.1186/1748-717X-7-165, PubMed 23017053

Publications 2011

1. Bratland A, Dueland S, Hollywood D, Flatmark K, Ree AH (2011)
   Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy
   Radiat Oncol, 6, 33
   DOI 10.1186/1748-717X-6-33, PubMed 21473790
2. Hjortland GO, Meza-Zepeda LA, Beiske K, Ree AH, Tveito S, Hoifodt H, Bohler PJ, Hole KH, Myklebost O, Fodstad O, Smeland S, Hovig E (2011)
   Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma
   BMC Cancer, 11, 455
   DOI 10.1186/1471-2407-11-455, PubMed 22014070
3. Røe K, Kakar M, Seierstad T, Ree AH, Olsen DR (2011)
   Early prediction of response to radiotherapy and androgen-deprivation therapy in prostate cancer by repeated functional MRI: a preclinical study
   Radiat Oncol, 6, 65
   DOI 10.1186/1748-717X-6-65, PubMed 21651782
4. Saelen MG, Flatmark K, Folkvord S, de Wijn R, Rasmussen H, Fodstad Ø, Ree AH (2011)
   Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination
   Angiogenesis, 14 (4), 481-9
   DOI 10.1007/s10456-011-9231-3, PubMed 21833622

Publications 2010

1. Bratland A, Vetrhus T, Grøholt KK, Ree AH (2010)
   Preoperative radiotherapy in rectal signet-ring cell carcinoma - magnetic resonance imaging and treatment outcome: Report of six cases
   Acta Oncol, 49 (1), 42-9
   DOI 10.3109/02841860903081897, PubMed 20100143
2. Flatmark K, Ree AH (2010)
   Radiosensitizing drugs: lessons to be learned from the oxaliplatin story
   J Clin Oncol, 28 (29), e577-8; author reply e581-3
   DOI 10.1200/JCO.2010.30.0921, PubMed 20733124
3. Folkvord S, Flatmark K, Dueland S, de Wijn R, Grøholt KK, Hole KH, Nesland JM, Ruijtenbeek R, Boender PJ, Johansen M, Giercksky KE, Ree AH (2010)
   Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling
   Int J Radiat Oncol Biol Phys, 78 (2), 555-62
   DOI 10.1016/j.ijrobp.2010.04.036, PubMed 20675069
4. Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, Abrahamsen TW, Flatmark K (2010)
   Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study
   Lancet Oncol, 11 (5), 459-64
   DOI 10.1016/S1470-2045(10)70058-9, PubMed 20378407
5. Røe K, Aleksandersen TB, Kristian A, Nilsen LB, Seierstad T, Qu H, Ree AH, Olsen DR, Malinen E (2010)
   Preclinical dynamic 18F-FDG PET - tumor characterization and radiotherapy response assessment by kinetic compartment analysis
   Acta Oncol, 49 (7), 914-21
   DOI 10.3109/0284186X.2010.498831, PubMed 20831478
6. Røe K, Seierstad T, Kristian A, Mikalsen LT, Mælandsmo GM, van der Kogel AJ, Ree AH, Olsen DR (2010)
   Longitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditions
   Neoplasia, 12 (10), 818-25
   DOI 10.1593/neo.10484, PubMed 20927320

Publications 2009

1. Bergamaschi A, Hjortland GO, Triulzi T, Sørlie T, Johnsen H, Ree AH, Russnes HG, Tronnes S, Maelandsmo GM, Fodstad O, Borresen-Dale AL, Engebraaten O (2009)
   Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models
   Mol Oncol, 3 (5-6), 469-82
   DOI 10.1016/j.molonc.2009.07.003, PubMed 19713161
2. Bratland A, Boender PJ, Høifødt HK, Østensen IH, Ruijtenbeek R, Wang MY, Berg JP, Lilleby W, Fodstad Ø, Ree AH (2009)
   Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling
   Clin Exp Metastasis, 26 (5), 485-96
   DOI 10.1007/s10585-009-9248-9, PubMed 19294521
3. Folkvord S, Ree AH, Furre T, Halvorsen T, Flatmark K (2009)
   Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status
   Int J Radiat Oncol Biol Phys, 74 (2), 546-52
   DOI 10.1016/j.ijrobp.2009.01.068, PubMed 19427556
4. Seierstad T, Hole KH, Saelen E, Ree AH, Flatmark K, Malinen E (2009)
   MR-guided simultaneous integrated boost in preoperative radiotherapy of locally advanced rectal cancer following neoadjuvant chemotherapy
   Radiother Oncol, 93 (2), 279-84
   DOI 10.1016/j.radonc.2009.08.046, PubMed 19800704

Publications 2008

1. Ree AH (2008)
   Highly proliferative neuroendocrine carcinoma - influence of radiotherapy fractionation on tumor response
   Radiat Oncol, 3, 13
   DOI 10.1186/1748-717X-3-13, PubMed 18489745
2. Ree AH, Bratland A, Dueland S (2008)
   [Molecular targeted therapy in colorectal cancer]
   Tidsskr Nor Laegeforen, 128 (2), 190-3
   PubMed 18202731
3. Ree AH, Folkvord S, Flatmark K (2008)
   HDAC2 deficiency and histone acetylation
   Nat Genet, 40 (7), 812-3; author reply 813
   DOI 10.1038/ng0708-812, PubMed 18583969
4. Seierstad T, Røe K, Sitter B, Halgunset J, Flatmark K, Ree AH, Olsen DR, Gribbestad IS, Bathen TF (2008)
   Principal component analysis for the comparison of metabolic profiles from human rectal cancer biopsies and colorectal xenografts using high-resolution magic angle spinning 1H magnetic resonance spectroscopy
   Mol Cancer, 7, 33
   DOI 10.1186/1476-4598-7-33, PubMed 18439252

Publications 2007

1. Folkvord S, Flatmark K, Seierstad T, Røe K, Rasmussen H, Ree AH (2007)
   Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?
   Radiother Oncol, 86 (3), 428-34
   DOI 10.1016/j.radonc.2007.10.012, PubMed 18006097
2. Paulsen T, Ree AH, Kaern J, Kjaerheim K, Bassarova A, Berner A, Haldorsen T, Tropé C, Nesland JM (2007)
   Expression of matrix metalloproteinase-2 in serous borderline ovarian tumors is associated with noninvasive implant formation
   Eur J Gynaecol Oncol, 28 (5), 356-63
   PubMed 17966213

Publications 2006

1. Dahm AE, Iversen N, Birkenes B, Ree AH, Sandset PM (2006)
   Estrogens, selective estrogen receptor modulators, and a selective estrogen receptor down-regulator inhibit endothelial production of tissue factor pathway inhibitor 1
   BMC Cardiovasc Disord, 6, 40
   DOI 10.1186/1471-2261-6-40, PubMed 17029634
2. Flatmark K, Nome RV, Folkvord S, Bratland A, Rasmussen H, Ellefsen MS, Fodstad Ø, Ree AH (2006)
   Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition
   Radiat Oncol, 1, 25
   DOI 10.1186/1748-717X-1-25, PubMed 16887021
3. Ree AH (2006)
   A complex case of rectal neuroendocrine carcinoma with terminal delirium
   Nat Clin Pract Gastroenterol Hepatol, 3 (7), 408-13; quiz 414
   DOI 10.1038/ncpgasthep0525, PubMed 16819503
4. Ree AH, Stokke T, Bratland A, Patzke S, Nome RV, Folkvord S, Meza-Zepeda LA, Flatmark K, Fodstad O, Andersson Y (2006)
   DNA damage responses in cell cycle G2 phase and mitosis--tracking and targeting
   Anticancer Res, 26 (3A), 1909-16
   PubMed 16827124

Publications 2005

1. Lyng H, Landsverk KS, Kristiansen E, DeAngelis PM, Ree AH, Myklebost O, Hovig E, Stokke T (2005)
   Response of malignant B lymphocytes to ionizing radiation: gene expression and genotype
   Int J Cancer, 115 (6), 935-42
   DOI 10.1002/ijc.20962, PubMed 15723354
2. Nome RV, Bratland A, Harman G, Fodstad O, Andersson Y, Ree AH (2005)
   Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death
   Mol Cancer Ther, 4 (8), 1231-8
   DOI 10.1158/1535-7163.MCT-04-0304, PubMed 16093439
3. Porojnicu AC, Robsahm TE, Ree AH, Moan J (2005)
   Season of diagnosis is a prognostic factor in Hodgkin's lymphoma: a possible role of sun-induced vitamin D
   Br J Cancer, 93 (5), 571-4
   DOI 10.1038/sj.bjc.6602722, PubMed 16136030

Publications 2004

1. DeMasters GA, Gupta MS, Jones KR, Cabot M, Wang H, Gennings C, Park M, Bratland A, Ree AH, Gewirtz DA (2004)
   Potentiation of cell killing by fractionated radiation and suppression of proliferative recovery in MCF-7 breast tumor cells by the Vitamin D3 analog EB 1089
   J Steroid Biochem Mol Biol, 92 (5), 365-74
   DOI 10.1016/j.jsbmb.2004.07.011, PubMed 15698541
2. Johansson CC, Yndestad A, Enserink JM, Ree AH, Aukrust P, Taskén K (2004)
   The epidermal growth factor-like growth factor amphiregulin is strongly induced by the adenosine 3',5'-monophosphate pathway in various cell types
   Endocrinology, 145 (11), 5177-84
   DOI 10.1210/en.2004-0232, PubMed 15284208
3. Ree AH (2004)
   [Cell cycle-targeted therapy]
   Tidsskr Nor Laegeforen, 124 (19), 2479-82
   PubMed 15477884
4. Ree AH, Bratland A, Nome RV, Stokke T, Fodstad O, Andersson Y (2004)
   Inhibitory targeting of checkpoint kinase signaling overrides radiation-induced cell cycle gene regulation: a therapeutic strategy in tumor cell radiosensitization?
   Radiother Oncol, 72 (3), 305-10
   DOI 10.1016/j.radonc.2004.07.002, PubMed 15450729
5. Ree AH, Bratland A, Solberg Landsverk K, Fodstad O (2004)
   Ionizing radiation inhibits the PLK cell cycle gene in a G2 checkpoint-dependent manner
   Anticancer Res, 24 (2B), 555-62
   PubMed 15160994

Publications 2003

1. Bratland A, Ragnhildstveit E, Bjørnland K, Andersen K, Maelandsmo GM, Fodstad O, Saatcioglu F, Ree AH (2003)
   The metalloproteinase inhibitor TIMP-2 is down-regulated by androgens in LNCaP prostate carcinoma cells
   Clin Exp Metastasis, 20 (6), 541-7
   DOI 10.1023/a:1025860214891, PubMed 14598888
2. Ree AH, Bratland A, Nome RV, Stokke T, Fodstad Ø (2003)
   Repression of mRNA for the PLK cell cycle gene after DNA damage requires BRCA1
   Oncogene, 22 (55), 8952-5
   DOI 10.1038/sj.onc.1207000, PubMed 14654792

Publications 2002

1. Ree AH, Bratland A, Kroes RA, Aasheim HC, Flørenes VA, Moskal JR, Fodstad O, Bruland OS, Maelandsmo GM (2002)
   Clinical and cell line specific expression profiles of a human gene identified in experimental central nervous system metastases
   Anticancer Res, 22 (4), 1949-57
   PubMed 12174869
2. Ree AH, Engebraaten O, Hovig E, Fodstad Ø (2002)
   Differential display analysis of breast carcinoma cells enriched by immunomagnetic target cell selection: gene expression profiles in bone marrow target cells
   Int J Cancer, 97 (1), 28-33
   DOI 10.1002/ijc.1564, PubMed 11774240

Publications 2001

1. Bjørnland K, Bratland A, Rugnes E, Pettersen S, Johansen HT, Aasen AO, Fodstad Ø, Ree AH, Maelandsmo GM (2001)
   Expression of matrix metalloproteinases and the metastasis-associated gene S100A4 in human neuroblastoma and primitive neuroectodermal tumor cells
   J Pediatr Surg, 36 (7), 1040-4
   DOI 10.1053/jpsu.2001.24735, PubMed 11431772
2. Glauser R, Rée A, Lundgren A, Gottlow J, Hämmerle CH, Schärer P (2001)
   Immediate occlusal loading of Brånemark implants applied in various jawbone regions: a prospective, 1-year clinical study
   Clin Implant Dent Relat Res, 3 (4), 204-13
   DOI 10.1111/j.1708-8208.2001.tb00142.x, PubMed 11887657

Publications 2000

1. Bratland A, Risberg K, Maelandsmo GM, Gützkow KB, Olsen OE, Moghaddam A, Wang MY, Hansen CM, Blomhoff HK, Berg JP, Fodstad O, Ree AH (2000)
   Expression of a novel factor, com1, is regulated by 1,25-dihydroxyvitamin D3 in breast cancer cells
   Cancer Res, 60 (19), 5578-83
   PubMed 11034106
2. Grønning LM, Wang JE, Ree AH, Haugen TB, Taskén K, Taskén KA (2000)
   Regulation of tissue inhibitor of metalloproteinases-1 in rat Sertoli cells: induction by germ cell residual bodies, interleukin-1alpha, and second messengers
   Biol Reprod, 62 (4), 1040-6
   DOI 10.1095/biolreprod62.4.1040, PubMed 10727275
3. Ree AH, Pacheco MM, Tvermyr M, Fodstad O, Brentani MM (2000)
   Expression of a novel factor, com1, in early tumor progression of breast cancer
   Clin Cancer Res, 6 (5), 1778-83
   PubMed 10815897

Publications 1999

1. Ree AH, Hansson V, Walaas SI, Eskild W, Taskén KA (1999)
   Calcium/phospholipid-dependent protein kinases in rat Sertoli cells: regulation of androgen receptor messenger ribonucleic acid
   Biol Reprod, 60 (5), 1257-62
   DOI 10.1095/biolreprod60.5.1257, PubMed 10208993
2. Ree AH, Tvermyr M, Engebraaten O, Rooman M, Røsok O, Hovig E, Meza-Zepeda LA, Bruland OS, Fodstad O (1999)
   Expression of a novel factor in human breast cancer cells with metastatic potential
   Cancer Res, 59 (18), 4675-80
   PubMed 10493524
3. Røsok O, Pedeutour F, Ree AH, Aasheim HC (1999)
   Identification and characterization of TESK2, a novel member of the LIMK/TESK family of protein kinases, predominantly expressed in testis
   Genomics, 61 (1), 44-54
   DOI 10.1006/geno.1999.5922, PubMed 10512679
4. Ståhl S, Odeberg J, Larsson M, Røsok O, Ree AH, Lundeberg J (1999)
   Solid-phase differential display and bacterial expression systems in selection and functional analysis of cDNAs
   Methods Enzymol, 303, 495-511
   DOI 10.1016/s0076-6879(99)03030-x, PubMed 10349662

Publications 1998

1. Bjørnland K, Lehne G, Johansen HT, Fodstad O, Rugstad HE, Aasen AO, Ree AH (1998)
   Human hepatoma cells rich in P-glycoprotein display enhanced in vitro invasive properties compared to P-glycoprotein-poor hepatoma cells
   Oncol Res, 10 (5), 255-62
   PubMed 9802060
2. Ree AH, Bjørnland K, Brünner N, Johansen HT, Pedersen KB, Aasen AO, Fodstad O (1998)
   Regulation of tissue-degrading factors and in vitro invasiveness in progression of breast cancer cells
   Clin Exp Metastasis, 16 (3), 205-15
   DOI 10.1023/a:1006584624061, PubMed 9568638

Publications 1997

1. Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O (1997)
   High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases
   Clin Cancer Res, 3 (9), 1623-8
   PubMed 9815852

Publications 1996

1. Ree AH, Maelandsmo GM, Fodstad O (1996)
   Regulation of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in MCF-7 cells: comparison with regulatory mechanisms of pS2 expression
   Clin Exp Metastasis, 14 (4), 381-8
   DOI 10.1007/BF00123397, PubMed 8878412

Publications 1994

1. Berg JP, Ree AH, Sandvik JA, Taskén K, Landmark BF, Torjesen PA, Haug E (1994)
   1,25-dihydroxyvitamin D3 alters the effect of cAMP in thyroid cells by increasing the regulatory subunit type II beta of the cAMP-dependent protein kinase
   J Biol Chem, 269 (51), 32233-8
   PubMed 7798223
2. Berg JP, Sandvik JA, Ree AH, Sørnes G, Bjøro T, Torjesen PA, Gordeladze JO, Haug E (1994)
   1,25-Dihydroxyvitamin D3 attenuates adenylyl cyclase activity in rat thyroid cells: reduction of thyrotropin receptor number and increase in guanine nucleotide-binding protein Gi-2 alpha
   Endocrinology, 135 (2), 595-602
   DOI 10.1210/endo.135.2.8033808, PubMed 8033808
3. Ree AH, Taskén K, Hansson V (1994)
   Regulation of glucocorticoid receptor (GR) mRNA and protein levels by phorbol ester in MCF-7 cells. Mechanism of GR mRNA induction and decay
   J Steroid Biochem Mol Biol, 48 (1), 23-9
   DOI 10.1016/0960-0760(94)90247-x, PubMed 8136303

Publications 1992

1. Kise NJ, Bergsmark JK, Endreseth BH, Reinertsen KV, Ugelstad TP, Ree AH (1992)
   [Living and dying alone. An epidemiological study of deaths outside institutions in Oslo in 1989]
   Tidsskr Nor Laegeforen, 112 (5), 616-9
   PubMed 1557724
2. Ree AH, Knutsen HK, Landmark BF, Eskild W, Hansson V (1992)
   Down-regulation of messenger ribonucleic acid (mRNA) for the estrogen receptor (ER) by phorbol ester requires ongoing RNA synthesis but not protein synthesis. Is hormonal control of ER mRNA degradation mediated by an RNA molecule?
   Endocrinology, 131 (4), 1810-4
   DOI 10.1210/endo.131.4.1382961, PubMed 1382961

Publications 1991

1. Eskild W, Ree AH, Levy FO, Jahnsen T, Hansson V (1991)
   Cellular localization of mRNAs for retinoic acid receptor-alpha, cellular retinol-binding protein, and cellular retinoic acid-binding protein in rat testis: evidence for germ cell-specific mRNAs
   Biol Reprod, 44 (1), 53-61
   DOI 10.1095/biolreprod44.1.53, PubMed 1849753
2. Ree AH, Landmark BF, Walaas SI, Lahooti H, Eikvar L, Eskild W, Hansson V (1991)
   Down-regulation of messenger ribonucleic acid and protein levels for estrogen receptors by phorbol ester and calcium in MCF-7 cells
   Endocrinology, 129 (1), 339-44
   DOI 10.1210/endo-129-1-339, PubMed 2055193

Publications 1990

1. Ree AH, Frøysa A, Eskild W, Jahnsen T, Hansson V (1990)
   Biphasic regulation of the messenger ribonucleic acid coding for the estrogen receptor by cyclic adenosine 3':5'-monophosphate in tumor Leydig cells
   Cancer Res, 50 (5), 1528-31
   PubMed 2154326

Publications 1989

1. Levy FO, Ree AH, Eikvar L, Govindan MV, Jahnsen T, Hansson V (1989)
   Glucocorticoid receptors and glucocorticoid effects in rat Sertoli cells
   Endocrinology, 124 (1), 430-6
   DOI 10.1210/endo-124-1-430, PubMed 2909375
2. Ree AH, Landmark BF, Eskild W, Levy FO, Lahooti H, Jahnsen T, Aakvaag A, Hansson V (1989)
   Autologous down-regulation of messenger ribonucleic acid and protein levels for estrogen receptors in MCF-7 cells: an inverse correlation to progesterone receptor levels
   Endocrinology, 124 (5), 2577-83
   DOI 10.1210/endo-124-5-2577, PubMed 2651098

Publications by Kjersti Flatmark

146 publications found

Publications 2024

1. Dagenborg VJ, Brudvik KW, Lund-Andersen C, Torgunrud A, Lund-Iversen M, Flatmark K, Larsen SG, Yaqub S (2024)
   Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy and Liver Resection is a Treatment Option for Patients With Peritoneal and Liver Metastases From Colorectal Cancer
   Ann Surg, 280 (5), 745-752
   DOI 10.1097/SLA.0000000000006492, PubMed 39185557
2. Davidson B, Holth A, Hummel C, Flatmark K, Torgunrud A (2024)
   Different Frequency and Clinical Role for MTAP Loss in Pleural and Peritoneal Mesothelioma
   Appl Immunohistochem Mol Morphol, 32 (6), 280-284
   DOI 10.1097/PAI.0000000000001206, PubMed 38812360
3. Foote JB, Mattox TE, Keeton AB, Chen X, Smith F, Berry KL, Holmes T, Wang J, Huang CH, Ward AB, Mitra AK, Ramirez-Alcantara V, Hardy C, Fleten KG, Flatmark K, Yoon KJ, Sarvesh S, Nagaraju GP, Bandi DSR, Maxuitenko YY, Valiyaveettil J, Carstens JL, Buchsbaum DJ, Yang J, Zhou G et al. (2024)
   A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer
   bioRxiv
   DOI 10.1101/2023.05.17.541233, PubMed 38328254
4. Lund-Andersen C, Torgunrud A, Kanduri C, Dagenborg VJ, Frøysnes IS, Larsen MM, Davidson B, Larsen SG, Flatmark K (2024)
   Novel drug resistance mechanisms and drug targets in BRAF-mutated peritoneal metastasis from colorectal cancer
   J Transl Med, 22 (1), 646
   DOI 10.1186/s12967-024-05467-2, PubMed 38982444
5. Ree AH, Høye E, Esbensen Y, Beitnes AR, Negård A, Bernklev L, Tetlie LK, Fretland ÅA, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Nilsen HL, Flatmark K, Meltzer S (2024)
   Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade
   Oncoimmunology, 13 (1), 2372886
   DOI 10.1080/2162402X.2024.2372886, PubMed 38952672
6. Ree AH, Šaltytė Benth J, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Johansen C, Negård A, Bjørnetrø T, Nilsen HL, Berg JP, Flatmark K, Meltzer S (2024)
   First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial
   Br J Cancer, 130 (12), 1921-1928
   DOI 10.1038/s41416-024-02696-6, PubMed 38664577

Publications 2023

1. Arjona-Sanchez A, Martinez-López A, Moreno-Montilla MT, Mulsow J, Lozano-Lominchar P, Martínez-Torres B, Rau B, Canbay E, Sommariva A, Milione M, Deraco M, Sgarbura O, Torgunrud A, Kepenekian V, Carr NJ, Hoorens A, Delhorme JB, Wernert R, Goere D, Martin-Roman L, Cosyns S, Flatmark K, Davidson B, Khellaf L, Pereira-Perez F et al. (2023)
   External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification
   Eur J Surg Oncol, 49 (8), 1481-1488
   DOI 10.1016/j.ejso.2023.03.206, PubMed 36935222
2. Hyldbakk A, Fleten KG, Snipstad S, Åslund AKO, Davies CL, Flatmark K, Mørch Y (2023)
   Intraperitoneal administration of cabazitaxel-loaded nanoparticles in peritoneal metastasis models
   Nanomedicine, 48, 102656
   DOI 10.1016/j.nano.2023.102656, PubMed 36646195
3. Ito I, Yousef AM, Dickson PN, Naini ZA, White MG, Fleten KG, Flatmark K, Fournier KF, Fowlkes NW, Shen JP (2023)
   Antitumor activity of intraperitoneal paclitaxel in orthotopic patient-derived xenograft models of mucinous appendiceal adenocarcinoma
   bioRxiv
   DOI 10.1101/2023.02.01.526672, PubMed 36993681
4. Ito I, Yousef AMG, Chowdhury S, Dickson PN, Naini ZA, White MG, Fleten KG, Flatmark K, Fournier KF, Fowlkes NW, Shen JP (2023)
   Intraperitoneal Paclitaxel Is a Safe and Effective Therapeutic Strategy for Treating Mucinous Appendiceal Adenocarcinoma
   Cancer Res, 83 (19), 3184-3191
   DOI 10.1158/0008-5472.CAN-23-0013, PubMed 37433032
5. Nygaard V, Ree AH, Dagenborg VJ, Børresen-Dale AL, Edwin B, Fretland ÅA, Grzyb K, Haugen MH, Mælandsmo GM, Flatmark K (2023)
   A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases
   Cancer Res Commun, 3 (2), 235-244
   DOI 10.1158/2767-9764.CRC-22-0295, PubMed 36968142
6. Patrick-Brown TDJH, Mohamed F, Thrower A, Torgunrud A, Cosyns S, Canbay E, Villeneuve L, Flatmark K, Brandl A (2023)
   Determining a minimum data set for reporting clinical and radiologic data for pseudomyxoma peritonei
   Pleura Peritoneum, 8 (1), 1-9
   DOI 10.1515/pp-2022-0200, PubMed 37020469
7. Solbakken AM, Flatmark K (2023)
   ASO Author Reflections: Navigation-Assisted Surgery for Locally Advanced and Recurrent Rectal Cancer: The NAVI-LARRC Trial
   Ann Surg Oncol, 30 (12), 7633-7634
   DOI 10.1245/s10434-023-14058-2, PubMed 37573284
8. Solbakken AM, Sellevold S, Spasojevic M, Julsrud L, Emblemsvåg HL, Reims HM, Sørensen O, Thorgersen EB, Fauske L, Ågren JSM, Brennhovd B, Ryder T, Larsen SG, Flatmark K (2023)
   Navigation-Assisted Surgery for Locally Advanced Primary and Recurrent Rectal Cancer
   Ann Surg Oncol, 30 (12), 7602-7611
   DOI 10.1245/s10434-023-13964-9, PubMed 37481493
9. Thorgersen EB, Solbakken AM, Strøm TK, Goscinski M, Spasojevic M, Larsen SG, Flatmark K (2023)
   Short-term results after robot-assisted surgery for primary rectal cancers requiring beyond total mesorectal excision in multiple compartments
   Scand J Surg, 113 (1), 3-12
   DOI 10.1177/14574969231200654, PubMed 37787437

Publications 2022

1. Ambrosini M, Del Re M, Manca P, Hendifar A, Drilon A, Harada G, Ree AH, Klempner S, Mælandsmo GM, Flatmark K, Russnes HG, Cleary JM, Singh H, Sottotetti E, Martinetti A, Randon G, Sartore-Bianchi A, Capone I, Milione M, Di Bartolomeo M, Pietrantonio F (2022)
   ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series
   JCO Precis Oncol, 6 (1), e2200015
   DOI 10.1200/PO.22.00015, PubMed 35476549
2. Fleten KG, Hyldbakk A, Einen C, Benjakul S, Strand BL, Davies CL, Mørch Ý, Flatmark K (2022)
   Alginate Microsphere Encapsulation of Drug-Loaded Nanoparticles: A Novel Strategy for Intraperitoneal Drug Delivery
   Mar Drugs, 20 (12)
   DOI 10.3390/md20120744, PubMed 36547891
3. Fusser M, Øverbye A, Pandya AD, Mørch Ý, Borgos SE, Kildal W, Snipstad S, Sulheim E, Fleten KG, Askautrud HA, Engebraaten O, Flatmark K, Iversen TG, Sandvig K, Skotland T, Mælandsmo GM (2022)
   Corrigendum to "Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft", [Journal of Control Release, 293 (2019) 183-192]
   J Control Release, 349, 1
   DOI 10.1016/j.jconrel.2022.06.040, PubMed 35792388
4. Høye E, Dagenborg VJ, Torgunrud A, Lund-Andersen C, Fretland ÅA, Lorenz S, Edwin B, Hovig E, Fromm B, Inderberg EM, Greiff V, Ree AH, Flatmark K (2022)
   T cell receptor repertoire sequencing reveals chemotherapy-driven clonal expansion in colorectal liver metastases
   Gigascience, 12
   DOI 10.1093/gigascience/giad032, PubMed 37161965
5. Høye E, Fromm B, Böttger PHM, Domanska D, Torgunrud A, Lund-Andersen C, Abrahamsen TW, Fretland ÅA, Dagenborg VJ, Lorenz S, Edwin B, Hovig E, Flatmark K (2022)
   A comprehensive framework for analysis of microRNA sequencing data in metastatic colorectal cancer
   NAR Cancer, 4 (1), zcab051
   DOI 10.1093/narcan/zcab051, PubMed 35047825
6. Meltzer S, Negård A, Bakke KM, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Flatmark K, Ree AH (2022)
   Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer
   Br J Cancer, 127 (12), 2227-2233
   DOI 10.1038/s41416-022-02004-0, PubMed 36229579
7. Ree AH, Mælandsmo GM, Flatmark K, Russnes HG, Gómez Castañeda M, Aas E (2022)
   Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer - the MetAction precision medicine study
   Acta Oncol, 61 (8), 955-962
   DOI 10.1080/0284186X.2022.2098053, PubMed 35943168

Publications 2021

1. Andersson Y, Fleten KG, Abrahamsen TW, Reed W, Davidson B, Flatmark K (2021)
   Anti-Angiogenic Treatment in Pseudomyxoma Peritonei-Still a Strong Preclinical Rationale
   Cancers (Basel), 13 (11)
   DOI 10.3390/cancers13112819, PubMed 34198773
2. Dagenborg VJ, Marshall SE, Grzyb K, Fretland ÅA, Lund-Iversen M, Mælandsmo GM, Ree AH, Edwin B, Yaqub S, Flatmark K (2021)
   Low Concordance Between T-Cell Densities in Matched Primary Tumors and Liver Metastases in Microsatellite Stable Colorectal Cancer
   Front Oncol, 11, 671629
   DOI 10.3389/fonc.2021.671629, PubMed 34178659
3. Flatmark K, Torgunrud A, Fleten KG, Davidson B, Juul HV, Mensali N, Lund-Andersen C, Inderberg EM (2021)
   Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei
   J Immunother Cancer, 9 (10)
   DOI 10.1136/jitc-2021-003109, PubMed 34711663
4. Fleten KG, Eksteen JJ, Mauseth B, Camilio KA, Vasskog T, Sveinbjørnsson B, Rekdal Ø, Mælandsmo GM, Flatmark K (2021)
   Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer
   Sci Rep, 11 (1), 6731
   DOI 10.1038/s41598-021-86239-6, PubMed 33762676
5. Knuth F, Adde IA, Huynh BN, Groendahl AR, Winter RM, Negård A, Holmedal SH, Meltzer S, Ree AH, Flatmark K, Dueland S, Hole KH, Seierstad T, Redalen KR, Futsaether CM (2021)
   MRI-based automatic segmentation of rectal cancer using 2D U-Net on two independent cohorts
   Acta Oncol, 61 (2), 255-263
   DOI 10.1080/0284186X.2021.2013530, PubMed 34918621
6. Larsen SG, Goscinski MA, Dueland S, Steigen SE, Hofsli E, Torgunrud A, Lund-Iversen M, Dagenborg VJ, Flatmark K, Sorbye H (2021)
   Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients
   Br J Cancer, 126 (5), 726-735
   DOI 10.1038/s41416-021-01620-6, PubMed 34887523
7. Lund-Andersen C, Torgunrud A, Fleten KG, Flatmark K (2021)
   Omics analyses in peritoneal metastasis-utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review
   J Gastrointest Oncol, 12 (Suppl 1), S191-S203
   DOI 10.21037/jgo-20-136, PubMed 33968437
8. Mariathasan AB, Boye K, Dueland S, Flatmark K, Larsen SG (2021)
   Metastases in locally advanced rectal cancer undergoing curatively intended treatment
   Eur J Surg Oncol, 47 (9), 2377-2383
   DOI 10.1016/j.ejso.2021.04.023, PubMed 34049768
9. Meltzer S, Torgunrud A, Abrahamsson H, Solbakken AM, Flatmark K, Dueland S, Bakke KM, Bousquet PA, Negård A, Johansen C, Lyckander LG, Larsen FO, Schou JV, Redalen KR, Ree AH (2021)
   The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer
   Br J Cancer, 125 (2), 240-246
   DOI 10.1038/s41416-021-01377-y, PubMed 33837301
10. Sørensen O, Andersen AM, Larsen SG, Giercksky KE, Flatmark K (2021)
    Correction to: Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of highgrade pseudomyxoma peritonei
    Clin Exp Metastasis, 38 (2), 253
    DOI 10.1007/s10585-021-10084-0, PubMed 33649933
11. Thorgersen EB, Asvall J, Frøysnes IS, Schjalm C, Larsen SG, Dueland S, Andersson Y, Fodstad Ø, Mollnes TE, Flatmark K (2021)
    Increased Local Inflammatory Response to MOC31PE Immunotoxin After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Ann Surg Oncol, 28 (9), 5252-5262
    DOI 10.1245/s10434-021-10022-0, PubMed 34019185
12. Thorgersen EB, Flatmark K (2021)
    ASO Author Reflections: The Peritoneum is an Active Immunological Compartment
    Ann Surg Oncol, 28 (9), 5263-5264
    DOI 10.1245/s10434-021-10036-8, PubMed 33939046

Publications 2020

1. Aghayan DL, Kazaryan AM, Dagenborg VJ, Røsok BI, Fagerland MW, Waaler Bjørnelv GM, Kristiansen R, Flatmark K, Fretland ÅA, Edwin B, OSLO-COMET Survival Study Collaborators (2020)
   Long-Term Oncologic Outcomes After Laparoscopic Versus Open Resection for Colorectal Liver Metastases : A Randomized Trial
   Ann Intern Med, 174 (2), 175-182
   DOI 10.7326/M20-4011, PubMed 33197213
2. Dagenborg VJ, Marshall SE, Yaqub S, Grzyb K, Boye K, Lund-Iversen M, Høye E, Berstad AE, Fretland ÅA, Edwin B, Ree AH, Flatmark K (2020)
   Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases
   Cancer Biol Ther, 21 (5), 432-440
   DOI 10.1080/15384047.2020.1721252, PubMed 32098573
3. Flatmark K, Mohamed F (2020)
   ASO Author Reflections: Estimating the Prevalence of Pseudomyxoma Peritonei in Europe Using a Novel Statistical Method
   Ann Surg Oncol, 27 (Suppl 3), 771-772
   DOI 10.1245/s10434-020-08691-4, PubMed 32495284
4. Fleten KG, Lund-Andersen C, Waagene S, Abrahamsen TW, Mørch Y, Boye K, Torgunrud A, Flatmark K (2020)
   Experimental Treatment of Mucinous Peritoneal Metastases Using Patient-Derived Xenograft Models
   Transl Oncol, 13 (8), 100793
   DOI 10.1016/j.tranon.2020.100793, PubMed 32447231
5. Fromm B, Domanska D, Høye E, Ovchinnikov V, Kang W, Aparicio-Puerta E, Johansen M, Flatmark K, Mathelier A, Hovig E, Hackenberg M, Friedländer MR, Peterson KJ (2020)
   MirGeneDB 2.0: the metazoan microRNA complement
   Nucleic Acids Res, 48 (D1), D132-D141
   DOI 10.1093/nar/gkz885, PubMed 31598695
6. Fromm B, Domanska D, Høye E, Ovchinnikov V, Kang W, Aparicio-Puerta E, Johansen M, Flatmark K, Mathelier A, Hovig E, Hackenberg M, Friedländer MR, Peterson KJ (2020)
   MirGeneDB 2.0: the metazoan microRNA complement
   Nucleic Acids Res, 48 (D1), D1172
   DOI 10.1093/nar/gkz1016, PubMed 31642479
7. Meltzer S, Bjørnetrø T, Lyckander LG, Flatmark K, Dueland S, Samiappan R, Johansen C, Kalanxhi E, Ree AH, Redalen KR (2020)
   Corrigendum to "Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer" [Transl Oncol 12 (8) (2019) 1038-1044]
   Transl Oncol, 13 (1), 122-124
   DOI 10.1016/j.tranon.2019.09.005, PubMed 31843135
8. Patrick-Brown TDJH, Carr NJ, Swanson DM, Larsen S, Mohamed F, Flatmark K (2020)
   Estimating the Prevalence of Pseudomyxoma Peritonei in Europe Using a Novel Statistical Method
   Ann Surg Oncol, 28 (1), 252-257
   DOI 10.1245/s10434-020-08655-8, PubMed 32488520
9. Ree AH, Nygaard V, Boye K, Heinrich D, Dueland S, Bergheim IR, Johansen C, Beiske K, Negård A, Lund-Iversen M, Nygaard V, Hovig E, Nakken S, Nasser S, Julsrud L, Reisse CH, Ruud EA, Kristensen VN, Flørenes VA, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Russnes HG, Mælandsmo GM, Flatmark K (2020)
   Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
   Acta Oncol, 59 (7), 733-740
   DOI 10.1080/0284186X.2020.1742377, PubMed 32208873

Publications 2019

1. Abrahamsson H, Porojnicu AC, Lindstrøm JC, Dueland S, Flatmark K, Hole KH, Seierstad T, Moan J, Redalen KR, Meltzer S, Ree AH (2019)
   High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer
   BMC Cancer, 19 (1), 488
   DOI 10.1186/s12885-019-5724-z, PubMed 31122213
2. Aghayan DL, Fretland ÅA, Kazaryan AM, Sahakyan MA, Dagenborg VJ, Bjørnbeth BA, Flatmark K, Kristiansen R, Edwin B (2019)
   Laparoscopic versus open liver resection in the posterosuperior segments: a sub-group analysis from the OSLO-COMET randomized controlled trial
   HPB (Oxford), 21 (11), 1485-1490
   DOI 10.1016/j.hpb.2019.03.358, PubMed 30962136
3. Andersson Y, Inderberg EM, Kvalheim G, Herud TM, Engebraaten O, Flatmark K, Dueland S, Fodstad Ø (2019)
   Immune stimulatory effect of anti-EpCAM immunotoxin - improved overall survival of metastatic colorectal cancer patients
   Acta Oncol, 59 (4), 404-409
   DOI 10.1080/0284186X.2019.1704864, PubMed 31876430
4. Bains SJ, Abrahamsson H, Flatmark K, Dueland S, Hole KH, Seierstad T, Redalen KR, Meltzer S, Ree AH (2019)
   Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer
   Cancer Immunol Immunother, 69 (3), 355-364
   DOI 10.1007/s00262-019-02458-x, PubMed 31893287
5. Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM (2019)
   A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
   Transl Oncol, 12 (7), 951-958
   DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111
6. Frøysnes IS, Andersson Y, Larsen SG, Davidson B, Øien JT, Julsrud L, Fodstad Ø, Dueland S, Flatmark K (2019)
   ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis
   Eur J Surg Oncol, 47 (1), 134-138
   DOI 10.1016/j.ejso.2019.04.014, PubMed 31036394
7. Lund-Andersen C, Nakken S, Nygård S, Fromm B, Aasheim LB, Davidson B, Julsrud L, Abrahamsen TW, Kristensen AT, Dybdahl B, Larsen SG, Hovig E, Flatmark K (2019)
   Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response
   Cold Spring Harb Mol Case Stud, 5 (2)
   DOI 10.1101/mcs.a003566, PubMed 30862609
8. Meltzer S, Bakke KM, Rød KL, Negård A, Flatmark K, Solbakken AM, Kristensen AT, Fuglestad AJ, Kersten C, Dueland S, Seierstad T, Hole KH, Lyckander LG, Larsen FO, Schou JV, Patrick Brown D, Abrahamsson H, Redalen KR, Ree AH (2019)
   Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors?
   Clin Transl Radiat Oncol, 21, 5-10
   DOI 10.1016/j.ctro.2019.11.006, PubMed 31872084
9. Meltzer S, Bjørnetrø T, Lyckander LG, Flatmark K, Dueland S, Samiappan R, Johansen C, Kalanxhi E, Ree AH, Redalen KR (2019)
   Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer
   Transl Oncol, 12 (8), 1038-1044
   DOI 10.1016/j.tranon.2019.04.014, PubMed 31146167
10. Ree AH, Nygaard V, Russnes HG, Heinrich D, Nygaard V, Johansen C, Bergheim IR, Hovig E, Beiske K, Negård A, Børresen-Dale AL, Flatmark K, Mælandsmo GM (2019)
    Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
    Cancer Immunol Res, 7 (5), 701-706
    DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006
11. Sørensen O, Andersen AM, Larsen SG, Giercksky KE, Flatmark K (2019)
    Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of high-grade pseudomyxoma peritonei
    Clin Exp Metastasis, 36 (6), 511-518
    DOI 10.1007/s10585-019-09991-0, PubMed 31541325

Publications 2018

1. Bousquet PA, Meltzer S, Sønstevold L, Esbensen Y, Dueland S, Flatmark K, Sitter B, Bathen TF, Seierstad T, Redalen KR, Eide L, Ree AH (2018)
   Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer
   Transl Oncol, 12 (1), 76-83
   DOI 10.1016/j.tranon.2018.09.010, PubMed 30273860
2. Fretland ÅA, Dagenborg VJ, Bjørnelv GMW, Kazaryan AM, Kristiansen R, Fagerland MW, Hausken J, Tønnessen TI, Abildgaard A, Barkhatov L, Yaqub S, Røsok BI, Bjørnbeth BA, Andersen MH, Flatmark K, Aas E, Edwin B (2018)
   Laparoscopic Versus Open Resection for Colorectal Liver Metastases: The OSLO-COMET Randomized Controlled Trial
   Ann Surg, 267 (2), 199-207
   DOI 10.1097/SLA.0000000000002353, PubMed 28657937
3. Fusser M, Øverbye A, Pandya AD, Mørch Ý, Borgos SE, Kildal W, Snipstad S, Sulheim E, Fleten KG, Askautrud HA, Engebraaten O, Flatmark K, Iversen TG, Sandvig K, Skotland T, Mælandsmo GM (2018)
   Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft
   J Control Release, 293, 183-192
   DOI 10.1016/j.jconrel.2018.11.029, PubMed 30529259
4. Kalanxhi E, Meltzer S, Schou JV, Larsen FO, Dueland S, Flatmark K, Jensen BV, Hole KH, Seierstad T, Redalen KR, Nielsen DL, Ree AH (2018)
   Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer
   Br J Cancer, 118 (10), 1322-1328
   DOI 10.1038/s41416-018-0085-y, PubMed 29695770
5. Mariathasan AB, Boye K, Giercksky KE, Brennhovd B, Gullestad HP, Emblemsvåg HL, Grøholt KK, Dueland S, Flatmark K, Larsen SG (2018)
   Beyond total mesorectal excision in locally advanced rectal cancer with organ or pelvic side-wall involvement
   Eur J Surg Oncol, 44 (8), 1226-1232
   DOI 10.1016/j.ejso.2018.03.029, PubMed 29691115
6. Mikalsen SG, Mikalsen LTG, Sandvik JA, Aarnes EK, Fenne S, Flatmark K, Lyng H, Edin NFJ, Pettersen EO (2018)
   Low dose-rate irradiation with [³H]-labelled valine to selectively target hypoxic cells in a human colorectal cancer xenograft model
   Acta Oncol, 57 (9), 1216-1224
   DOI 10.1080/0284186X.2018.1457223, PubMed 29630428
7. Spasojevic M, Mariathasan AB, Goscinski M, Thorgersen EB, Solbakken AM, Gullestad HP, Ryder T, Flatmark K, Larsen SG (2018)
   Vertical Rectus Abdominis Musculocutaneous Flap Repair Improves Perineal Wound Healing after Abdominoperineal Resection for Irradiated Locally Advanced Rectal Cancer
   Ann Surg Oncol, 25 (5), 1357-1365
   DOI 10.1245/s10434-018-6363-3, PubMed 29497909

Publications 2017

1. Andersson Y, Haavardtun SI, Davidson B, Dørum A, Fleten KG, Fodstad Ø, Flatmark K (2017)
   MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer
   Oncotarget, 8 (37), 61800-61809
   DOI 10.18632/oncotarget.18694, PubMed 28977905
2. Bakke KM, Hole KH, Dueland S, Grøholt KK, Flatmark K, Ree AH, Seierstad T, Redalen KR (2017)
   Diffusion-weighted magnetic resonance imaging of rectal cancer: tumour volume and perfusion fraction predict chemoradiotherapy response and survival
   Acta Oncol, 56 (6), 813-818
   DOI 10.1080/0284186X.2017.1287951, PubMed 28464745
3. Flem-Karlsen K, Tekle C, Andersson Y, Flatmark K, Fodstad Ø, Nunes-Xavier CE (2017)
   Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells
   Pigment Cell Melanoma Res, 30 (5), 467-476
   DOI 10.1111/pcmr.12599, PubMed 28513992
4. Frøysnes IS, Andersson Y, Larsen SG, Davidson B, Øien JT, Olsen KH, Giercksky KE, Julsrud L, Fodstad Ø, Dueland S, Flatmark K (2017)
   Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial
   Ann Surg Oncol, 24 (7), 1916-1922
   DOI 10.1245/s10434-017-5814-6, PubMed 28224367
5. Graudenzi A, Cava C, Bertoli G, Fromm B, Flatmark K, Mauri G, Castiglioni I (2017)
   Pathway-based classification of breast cancer subtypes
   Front Biosci (Landmark Ed), 22 (10), 1697-1712
   DOI 10.2741/4566, PubMed 28410140
6. Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA et al. (2017)
   Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
   ESMO Open, 2 (2), e000158
   DOI 10.1136/esmoopen-2017-000158, PubMed 28761742
7. Østrup O, Dagenborg VJ, Rødland EA, Skarpeteig V, Silwal-Pandit L, Grzyb K, Berstad AE, Fretland ÅA, Mælandsmo GM, Børresen-Dale AL, Ree AH, Edwin B, Nygaard V, Flatmark K (2017)
   Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases
   Oncotarget, 8 (44), 76290-76304
   DOI 10.18632/oncotarget.19350, PubMed 29100312
8. Øverbye A, Holsæter AM, Markus F, Škalko-Basnet N, Iversen TG, Torgersen ML, Sønstevold T, Engebraaten O, Flatmark K, Mælandsmo GM, Skotland T, Sandvig K (2017)
   Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide
   Oncotarget, 8 (44), 76921-76934
   DOI 10.18632/oncotarget.20217, PubMed 29100358

Publications 2016

1. Boye K, Jacob H, Frikstad KA, Nesland JM, Maelandsmo GM, Dahl O, Nesbakken A, Flatmark K (2016)
   Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy
   Cancer Med, 5 (8), 1840-9
   DOI 10.1002/cam4.766, PubMed 27273130
2. Dueland S, Ree AH, Grøholt KK, Saelen MG, Folkvord S, Hole KH, Seierstad T, Larsen SG, Giercksky KE, Wiig JN, Boye K, Flatmark K (2016)
   Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome
   Clin Oncol (R Coll Radiol), 28 (8), 532-9
   DOI 10.1016/j.clon.2016.01.014, PubMed 26888115
3. Egeland EV, Flatmark K, Nesland JM, Flørenes VA, Mælandsmo GM, Boye K (2016)
   Expression and clinical significance of Wee1 in colorectal cancer
   Tumour Biol, 37 (9), 12133-12140
   DOI 10.1007/s13277-016-5081-3, PubMed 27220319
4. Flatmark K, Høye E, Fromm B (2016)
   microRNAs as cancer biomarkers
   Scand J Clin Lab Invest Suppl, 245, S80-3
   DOI 10.1080/00365513.2016.1210330, PubMed 27542003
5. Flatmark K, Saelen MG, Hole KH, Abrahamsen TW, Fleten KG, Hektoen HH, Redalen KR, Seierstad T, Dueland S, Ree AH (2016)
   Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity?
   Radiother Oncol, 119 (3), 505-11
   DOI 10.1016/j.radonc.2016.02.020, PubMed 26968754
6. Fleten KG, Bakke KM, Mælandsmo GM, Abildgaard A, Redalen KR, Flatmark K (2016)
   Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases
   Clin Exp Metastasis, 34 (1), 51-62
   DOI 10.1007/s10585-016-9829-3, PubMed 27812769
7. Frøysnes IS, Larsen SG, Spasojevic M, Dueland S, Flatmark K (2016)
   Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: Prognostic factors and oncologic outcome in a national patient cohort
   J Surg Oncol, 114 (2), 222-7
   DOI 10.1002/jso.24290, PubMed 27173150
8. Goscinski MA, Hole KH, Tønne E, Ryder T, Grøholt KK, Flatmark K (2016)
   Fibromatosis in vertical rectus abdominis myocutaneous flap imitating tumor recurrence after surgery for locally advanced rectal cancer: case report
   World J Surg Oncol, 14, 63
   DOI 10.1186/s12957-016-0818-4, PubMed 26940557
9. Jonsson M, Ragnum HB, Julin CH, Yeramian A, Clancy T, Frikstad KM, Seierstad T, Stokke T, Matias-Guiu X, Ree AH, Flatmark K, Lyng H (2016)
   Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition
   Br J Cancer, 115 (8), 929-939
   DOI 10.1038/bjc.2016.278, PubMed 27599042
10. Kalanxhi E, Hektoen HH, Meltzer S, Dueland S, Flatmark K, Ree AH (2016)
    Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening
    BMC Cancer, 16, 536
    DOI 10.1186/s12885-016-2601-x, PubMed 27461255
11. Kalanxhi E, Risberg K, Barua IS, Dueland S, Waagene S, Andersen SN, Pettersen SJ, Lindvall JM, Redalen KR, Flatmark K, Ree AH (2016)
    Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy
    Cancer Res Treat, 49 (2), 374-386
    DOI 10.4143/crt.2016.080, PubMed 27488871
12. Meltzer S, Kalanxhi E, Hektoen HH, Dueland S, Flatmark K, Redalen KR, Ree AH (2016)
    Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer
    Oncotarget, 7 (23), 34907-17
    DOI 10.18632/oncotarget.8995, PubMed 27145458
13. Thorgersen EB, Goscinski MA, Spasojevic M, Solbakken AM, Mariathasan AB, Boye K, Larsen SG, Flatmark K (2016)
    Deep Pelvic Surgical Site Infection After Radiotherapy and Surgery for Locally Advanced Rectal Cancer
    Ann Surg Oncol, 24 (3), 721-728
    DOI 10.1245/s10434-016-5621-5, PubMed 27766561

Publications 2015

1. Egeland EV, Boye K, Pettersen SJ, Haugen MH, Øyjord T, Malerød L, Flatmark K, Mælandsmo GM (2015)
   Enrichment of nuclear S100A4 during G2/M in colorectal cancer cells: possible association with cyclin B1 and centrosomes
   Clin Exp Metastasis, 32 (8), 755-67
   DOI 10.1007/s10585-015-9742-1, PubMed 26349943
2. Fretland ÅA, Kazaryan AM, Bjørnbeth BA, Flatmark K, Andersen MH, Tønnessen TI, Bjørnelv GM, Fagerland MW, Kristiansen R, Øyri K, Edwin B (2015)
   Open versus laparoscopic liver resection for colorectal liver metastases (the Oslo-CoMet Study): study protocol for a randomized controlled trial
   Trials, 16, 73
   DOI 10.1186/s13063-015-0577-5, PubMed 25872027
3. Fromm B, Billipp T, Peck LE, Johansen M, Tarver JE, King BL, Newcomb JM, Sempere LF, Flatmark K, Hovig E, Peterson KJ (2015)
   A Uniform System for the Annotation of Vertebrate microRNA Genes and the Evolution of the Human microRNAome
   Annu Rev Genet, 49, 213-42
   DOI 10.1146/annurev-genet-120213-092023, PubMed 26473382
4. Hektoen HH, Flatmark K, Andersson Y, Dueland S, Redalen KR, Ree AH (2015)
   Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer
   BMC Cancer, 15, 543
   DOI 10.1186/s12885-015-1557-6, PubMed 26205955
5. Hektoen HH, Ree AH, Redalen KR, Flatmark K (2015)
   Sulfamate inhibitor S4 influences carbonic anhydrase IX ectodomain shedding in colorectal carcinoma cells
   J Enzyme Inhib Med Chem, 31 (5), 779-86
   DOI 10.3109/14756366.2015.1069286, PubMed 26244271
6. Lambrecht JR, Larsen SG, Reiertsen O, Vaktskjold A, Julsrud L, Flatmark K (2015)
   Prophylactic mesh at end-colostomy construction reduces parastomal hernia rate: a randomized trial
   Colorectal Dis, 17 (10), O191-7
   DOI 10.1111/codi.13065, PubMed 26179984
7. Redalen KR, Sitter B, Bathen TF, Grøholt KK, Hole KH, Dueland S, Flatmark K, Ree AH, Seierstad T (2015)
   High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer
   Radiother Oncol, 118 (2), 393-8
   DOI 10.1016/j.radonc.2015.11.031, PubMed 26705680
8. Ree AH, Flatmark K, Saelen MG, Folkvord S, Dueland S, Geisler J, Redalen KR (2015)
   Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: opportunities for signaling-adapted therapies
   Crit Rev Oncol Hematol, 95 (1), 114-24
   DOI 10.1016/j.critrevonc.2015.01.003, PubMed 25624177
9. Seierstad T, Hole KH, Grøholt KK, Dueland S, Ree AH, Flatmark K, Redalen KR (2015)
   MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer
   Br J Radiol, 88 (1051), 20150097
   DOI 10.1259/bjr.20150097, PubMed 25899892

Publications 2014

1. Haugen MH, Boye K, Nesland JM, Pettersen SJ, Egeland EV, Tamhane T, Brix K, Maelandsmo GM, Flatmark K (2014)
   High expression of the cysteine proteinase legumain in colorectal cancer - implications for therapeutic targeting
   Eur J Cancer, 51 (1), 9-17
   DOI 10.1016/j.ejca.2014.10.020, PubMed 25466510
2. Ingebrigtsen VA, Boye K, Nesland JM, Nesbakken A, Flatmark K, Fodstad Ø (2014)
   B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome
   BMC Cancer, 14, 602
   DOI 10.1186/1471-2407-14-602, PubMed 25139714
3. Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, Ward C, Meehan J, Kunkler IH, Langdon SP, Ree AH, Flatmark K, Lyng H, Calzada MJ, Peso LD, Landazuri MO, Görlach A, Flamm H, Kieninger J, Urban G, Weltin A, Singleton DC, Haider S, Buffa FM, Harris AL et al. (2014)
   Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium
   J Enzyme Inhib Med Chem, 30 (5), 689-721
   DOI 10.3109/14756366.2014.966704, PubMed 25347767
4. Ree AH, Meltzer S, Flatmark K, Dueland S, Kalanxhi E (2014)
   Biomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networks
   Int J Mol Sci, 15 (12), 22835-56
   DOI 10.3390/ijms151222835, PubMed 25501337
5. Ree AH, Saelen MG, Kalanxhi E, Østensen IH, Schee K, Røe K, Abrahamsen TW, Dueland S, Flatmark K (2014)
   Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy
   PLoS One, 9 (2), e89750
   DOI 10.1371/journal.pone.0089750, PubMed 24587009
6. Wiiger MT, Bideli H, Fodstad O, Flatmark K, Andersson Y (2014)
   The MOC31PE immunotoxin reduces cell migration and induces gene expression and cell death in ovarian cancer cells
   J Ovarian Res, 7, 23
   DOI 10.1186/1757-2215-7-23, PubMed 24528603

Publications 2013

1. Flatmark K, Guldvik IJ, Svensson H, Fleten KG, Flørenes VA, Reed W, Giercksky KE, Fodstad Ø, Andersson Y (2013)
   Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies
   Int J Cancer, 133 (6), 1497-506
   DOI 10.1002/ijc.28158, PubMed 23494569
2. Friedman R, Boye K, Flatmark K (2013)
   Molecular modelling and simulations in cancer research
   Biochim Biophys Acta, 1836 (1), 1-14
   DOI 10.1016/j.bbcan.2013.02.001, PubMed 23416097
3. Haugen MH, Johansen HT, Pettersen SJ, Solberg R, Brix K, Flatmark K, Maelandsmo GM (2013)
   Nuclear legumain activity in colorectal cancer
   PLoS One, 8 (1), e52980
   DOI 10.1371/journal.pone.0052980, PubMed 23326369
4. Kongsgaard A, Borgen E, Mælandsmo GM, Flatmark K, Le H, Josefsen D, Solvoll I, Schirmer CB, Helland Å, Jørgensen L, Brustugun OT, Fodstad Ø, Boye K (2013)
   Clinical significance of disseminated tumour cells in non-small cell lung cancer
   Br J Cancer, 109 (5), 1264-70
   DOI 10.1038/bjc.2013.450, PubMed 23942067
5. Ragnum HB, Røe K, Holm R, Vlatkovic L, Nesland JM, Aarnes EK, Ree AH, Flatmark K, Seierstad T, Lilleby W, Lyng H (2013)
   Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer
   Int J Radiat Oncol Biol Phys, 87 (4), 753-60
   DOI 10.1016/j.ijrobp.2013.07.023, PubMed 24035332
6. Schee K, Lorenz S, Worren MM, Günther CC, Holden M, Hovig E, Fodstad O, Meza-Zepeda LA, Flatmark K (2013)
   Deep Sequencing the MicroRNA Transcriptome in Colorectal Cancer
   PLoS One, 8 (6), e66165
   DOI 10.1371/journal.pone.0066165, PubMed 23824282
7. Sørensen O, Andersen AM, Kristian A, Giercksky KE, Flatmark K (2013)
   Impact of hyperthermia on pharmacokinetics of intraperitoneal mitomycin C in rats investigated by microdialysis
   J Surg Oncol, 109 (6), 521-6
   DOI 10.1002/jso.23527, PubMed 24347444
8. Zhai H, Fesler A, Schee K, Fodstad O, Flatmark K, Ju J (2013)
   Clinical significance of long intergenic noncoding RNA-p21 in colorectal cancer
   Clin Colorectal Cancer, 12 (4), 261-6
   DOI 10.1016/j.clcc.2013.06.003, PubMed 24012455

Publications 2012

1. Boye K, Nesland JM, Sandstad B, Haugland Haugen M, Mælandsmo GM, Flatmark K (2012)
   EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer
   Br J Cancer, 107 (4), 667-74
   DOI 10.1038/bjc.2012.293, PubMed 22782346
2. Brusegard K, Stavnes HT, Nymoen DA, Flatmark K, Trope CG, Davidson B (2012)
   Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma
   Virchows Arch, 460 (2), 193-202
   DOI 10.1007/s00428-011-1191-x, PubMed 22249560
3. Ingebrigtsen VA, Boye K, Tekle C, Nesland JM, Flatmark K, Fodstad O (2012)
   B7-H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer
   Int J Cancer, 131 (11), 2528-36
   DOI 10.1002/ijc.27566, PubMed 22473715
4. Ree AH, Kristensen AT, Saelen MG, de Wijn R, Edvardsen H, Jovanovic J, Abrahamsen TW, Dueland S, Flatmark K (2012)
   Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer
   PLoS One, 7 (11), e50806
   DOI 10.1371/journal.pone.0050806, PubMed 23226389
5. Saelen MG, Ree AH, Kristian A, Fleten KG, Furre T, Hektoen HH, Flatmark K (2012)
   Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma
   Radiat Oncol, 7, 165
   DOI 10.1186/1748-717X-7-165, PubMed 23017053
6. Schee K, Boye K, Abrahamsen TW, Fodstad Ø, Flatmark K (2012)
   Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer
   BMC Cancer, 12, 505
   DOI 10.1186/1471-2407-12-505, PubMed 23121918
7. Schee K, Flatmark K, Holm R, Boye K, Paus E (2012)
   Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients (vol 33, pg 73, 2012)
   Tumor Biol., 33 (4), 1263-1264
   DOI 10.1007/s13277-012-0407-2
8. Sørensen O, Flatmark K, Reed W, Wiig JN, Dueland S, Giercksky KE, Larsen SG (2012)
   Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in Pseudomyxoma peritonei
   Eur J Surg Oncol, 38 (10), 969-76
   DOI 10.1016/j.ejso.2012.06.552, PubMed 22763244

Publications 2011

1. Bratland A, Dueland S, Hollywood D, Flatmark K, Ree AH (2011)
   Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy
   Radiat Oncol, 6, 33
   DOI 10.1186/1748-717X-6-33, PubMed 21473790
2. Flatmark K, Borgen E, Nesland JM, Rasmussen H, Johannessen HO, Bukholm I, Rosales R, Hårklau L, Jacobsen HJ, Sandstad B, Boye K, Fodstad Ø (2011)
   Disseminated tumour cells as a prognostic biomarker in colorectal cancer
   Br J Cancer, 104 (9), 1434-9
   DOI 10.1038/bjc.2011.97, PubMed 21448171
3. Saelen MG, Flatmark K, Folkvord S, de Wijn R, Rasmussen H, Fodstad Ø, Ree AH (2011)
   Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination
   Angiogenesis, 14 (4), 481-9
   DOI 10.1007/s10456-011-9231-3, PubMed 21833622
4. Schee K, Flatmark K, Holm R, Boye K, Paus E (2011)
   Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients
   Tumour Biol, 33 (1), 73-83
   DOI 10.1007/s13277-011-0247-5, PubMed 22006279
5. Wiig JN, Larsen SG, Dueland S, Flatmark K, Giercksky KE (2011)
   Salvage surgery for locally recurrent rectal cancer: total mesorectal excision during the primary operation does not influence the outcome
   Colorectal Dis, 13 (5), 506-11
   DOI 10.1111/j.1463-1318.2010.02256.x, PubMed 20236148

Publications 2010

1. Berge G, Costea DE, Berg M, Rasmussen H, Grotterød I, Lothe RA, Mælandsmo GM, Flatmark K (2010)
   Coexpression and nuclear colocalization of metastasis-promoting protein S100A4 and p53 without mutual regulation in colorectal carcinoma
   Amino Acids, 41 (4), 875-84
   DOI 10.1007/s00726-010-0514-6, PubMed 20191297
2. Boye K, Nesland JM, Sandstad B, Mælandsmo GM, Flatmark K (2010)
   Nuclear S100A4 is a novel prognostic marker in colorectal cancer
   Eur J Cancer, 46 (16), 2919-25
   DOI 10.1016/j.ejca.2010.07.013, PubMed 20719498
3. Flatmark K, Davidson B, Kristian A, Stavnes HT, Førsund M, Reed W (2010)
   Exploring the peritoneal surface malignancy phenotype--a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models
   Hum Pathol, 41 (8), 1109-19
   DOI 10.1016/j.humpath.2009.12.013, PubMed 20338618
4. Flatmark K, Ree AH (2010)
   Radiosensitizing drugs: lessons to be learned from the oxaliplatin story
   J Clin Oncol, 28 (29), e577-8; author reply e581-3
   DOI 10.1200/JCO.2010.30.0921, PubMed 20733124
5. Folkvord S, Flatmark K, Dueland S, de Wijn R, Grøholt KK, Hole KH, Nesland JM, Ruijtenbeek R, Boender PJ, Johansen M, Giercksky KE, Ree AH (2010)
   Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling
   Int J Radiat Oncol Biol Phys, 78 (2), 555-62
   DOI 10.1016/j.ijrobp.2010.04.036, PubMed 20675069
6. Paus E, Haugen MH, Olsen KH, Flatmark K, Maelandsmo GM, Nilsson O, Röijer E, Lundin M, Fermér C, Samsonova M, Lebedin Y, Stigbrand T (2010)
   TD-11 workshop report: characterization of monoclonal antibodies to S100 proteins
   Tumour Biol, 32 (1), 1-12
   DOI 10.1007/s13277-010-0073-1, PubMed 20652782
7. Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, Abrahamsen TW, Flatmark K (2010)
   Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study
   Lancet Oncol, 11 (5), 459-64
   DOI 10.1016/S1470-2045(10)70058-9, PubMed 20378407
8. Schee K, Fodstad Ø, Flatmark K (2010)
   MicroRNAs as biomarkers in colorectal cancer
   Am J Pathol, 177 (4), 1592-9
   DOI 10.2353/ajpath.2010.100024, PubMed 20829435
9. Sørensen O, Andersen A, Olsen H, Alexandr K, Ekstrøm PO, Giercksky KE, Flatmark K (2010)
   Validation and use of microdialysis for determination of pharmacokinetic properties of the chemotherapeutic agent mitomycin C - an experimental study
   BMC Cancer, 10, 469
   DOI 10.1186/1471-2407-10-469, PubMed 20809961

Publications 2009

1. Folkvord S, Ree AH, Furre T, Halvorsen T, Flatmark K (2009)
   Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status
   Int J Radiat Oncol Biol Phys, 74 (2), 546-52
   DOI 10.1016/j.ijrobp.2009.01.068, PubMed 19427556
2. Maelandsmo GM, Flørenes VA, Nguyen MT, Flatmark K, Davidson B (2009)
   Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites
   Tumour Biol, 30 (1), 15-25
   DOI 10.1159/000199447, PubMed 19194111
3. Seierstad T, Hole KH, Saelen E, Ree AH, Flatmark K, Malinen E (2009)
   MR-guided simultaneous integrated boost in preoperative radiotherapy of locally advanced rectal cancer following neoadjuvant chemotherapy
   Radiother Oncol, 93 (2), 279-84
   DOI 10.1016/j.radonc.2009.08.046, PubMed 19800704

Publications 2008

1. Brunsvig PF, Flatmark K, Aamdal S, Høifødt H, Le H, Jakobsen E, Sandstad B, Fodstad O (2008)
   Bone marrow micrometastases in advanced stage non-small cell lung carcinoma patients
   Lung Cancer, 61 (2), 170-6
   DOI 10.1016/j.lungcan.2007.12.018, PubMed 18261824
2. Haugen MH, Flatmark K, Mikalsen SO, Malandsmo GM (2008)
   The metastasis-associated protein S100A4 exists in several charged variants suggesting the presence of posttranslational modifications
   BMC Cancer, 8, 172
   DOI 10.1186/1471-2407-8-172, PubMed 18554396
3. Ree AH, Folkvord S, Flatmark K (2008)
   HDAC2 deficiency and histone acetylation
   Nat Genet, 40 (7), 812-3; author reply 813
   DOI 10.1038/ng0708-812, PubMed 18583969
4. Seierstad T, Røe K, Sitter B, Halgunset J, Flatmark K, Ree AH, Olsen DR, Gribbestad IS, Bathen TF (2008)
   Principal component analysis for the comparison of metabolic profiles from human rectal cancer biopsies and colorectal xenografts using high-resolution magic angle spinning 1H magnetic resonance spectroscopy
   Mol Cancer, 7, 33
   DOI 10.1186/1476-4598-7-33, PubMed 18439252

Publications 2007

1. Flatmark K, Reed W, Halvorsen T, Sørensen O, Wiig JN, Larsen SG, Fodstad Ø, Giercksky KE (2007)
   Pseudomyxoma peritonei--two novel orthotopic mouse models portray the PMCA-I histopathologic subtype
   BMC Cancer, 7, 116
   DOI 10.1186/1471-2407-7-116, PubMed 17603904
2. Folkvord S, Flatmark K, Seierstad T, Røe K, Rasmussen H, Ree AH (2007)
   Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?
   Radiother Oncol, 86 (3), 428-34
   DOI 10.1016/j.radonc.2007.10.012, PubMed 18006097
3. Seierstad T, Folkvord S, Røe K, Flatmark K, Skretting A, Olsen DR (2007)
   Early changes in apparent diffusion coefficient predict the quantitative antitumoral activity of capecitabine, oxaliplatin, and irradiation in HT29 xenografts in athymic nude mice
   Neoplasia, 9 (5), 392-400
   DOI 10.1593/neo.07154, PubMed 17534444

Publications 2006

1. Flatmark K, Nome RV, Folkvord S, Bratland A, Rasmussen H, Ellefsen MS, Fodstad Ø, Ree AH (2006)
   Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition
   Radiat Oncol, 1, 25
   DOI 10.1186/1748-717X-1-25, PubMed 16887021
2. Ree AH, Stokke T, Bratland A, Patzke S, Nome RV, Folkvord S, Meza-Zepeda LA, Flatmark K, Fodstad O, Andersson Y (2006)
   DNA damage responses in cell cycle G2 phase and mitosis--tracking and targeting
   Anticancer Res, 26 (3A), 1909-16
   PubMed 16827124